OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Discovery is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
AI-Supported Mammography “Safe,” Cuts Workload	6470
HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion	681
Mutation-Driven Alveolar Cell Reprogramming Dictates Lung Cancer Progression	349
Succinyl-CoA and Cobalamin Are Biomarkers That Improve Anal Cancer Screening	312
Human Tumor Cells Display an Oncogene-like Addiction to Aneuploidy	253
Q&A: Philip Greenberg on T Cells, IO's Future	246
Shattered Chromosomes Undergo Mitotic Tethering during Chromothripsis	229
PARADIGM Identifies Associations between Drugs, the Microbiome, and Mortality	222
Air Pollution Promotes Oncogenic Expansion of Mutant Lung Progenitor Cells	210
Transposable Element Signatures Define Stages of T-cell Exhaustion	206
Probing Clonal Hematopoiesis in Liquid Biopsy	205
Collagen Receptor Implicated in Immune Exclusion	204
Low-Glycemic Diets Restrict Tumor Growth through Altered Lipid Metabolism	200
Drafting a Blueprint for European Cancer Research	194
IL7 Genetic Variation Predicts Immune-Related Adverse Events	194
Dendritic Cell Circadian Rhythm Governs the Antitumor Immune Response	190
Mouse Models Provide Insight into Factors Affecting BiTE Efficacy	180
Highlighted research articles	171
Proteostasis Network Modulation Promotes Resistance to KRAS Inhibitors	167
REFLECTions on Combination Therapies Empowered by Data Sharing	166
Highlighted research articles	160
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	150
Correction: Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer	146
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers	146
PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway	145

A Guide to Extrachromosomal DNA: Cancer’s Dynamic Circular Genome	143
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC	143
GIST: Molecular Profiling Suggests 2nd Therapy	142
Exome Sequencing IDs Hidden Disease Variants	137
Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response	136
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors	134
Trispecifics Improve Immune-Cell Engagement	128
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma	128
Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer	128
Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta	127
An NK-cell Therapy for CD30+ Lymphomas	126
RAS Drives Malignancy through Altered Stem Cell/Microenvironment Cross-talk	125
Lymph Node Metastasis Induces Immune Tolerance and Distant Metastasis	125
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?	124
The 3D Revolution in Cancer Discovery	123
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression	121
Intrinsic Properties of the Lymph Node Render It Immunologically Susceptible to Metastasis	121
Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency	118
Structure of the Tumor Stroma Predicts Invasive Breast Cancer Relapse	117
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma	116
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression	113
CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma	112
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy	111
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	109
Multicellular Spatial Organization Determines Immunotherapy Response	107
Presurgery Plus Postsurgery Immunotherapy Ups Survival in NSCLC	107
In This Issue	105
Chronic Inflammation Drives TP53-Mutant Leukemic Evolution	105
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors	105
Tumor-Derived Extracellular Vesicles and Particles Inhibit Liver Function	104
The Proteasome Regulator PSME4 Modulates Antitumor Immunity	104
Intestinal Microbiome Inhibits CD8+ T Cells via the Calcineurin–NFAT Axis	103
New Strategy May Thwart Glioblastoma Resistance	101
FMRP Depletion Reprograms an Immunosuppressive Microenvironment	101
Hyperactivation of Oncogenic Pathways Hinders Cancer Cell Survival	99
TILs Outperform Ipilimumab in Melanoma	99
Lymph Node–Specific IFNγ Levels Affect CD8+ T-cell Priming against Tumors	96
What's Next for Sotorasib in NSCLC?	93
Revumenib Is Safe and Efficacious, but MEN1 Mutations Mediate Resistance	93
Aged Lungs Enable Metastatic Outgrowth of Dormant Melanoma Cells	90
Biomarker Testing Falls Short in NSCLC	90
In This Issue	89
Cancer in the Prime of Life: Etiologic Insights and Supportive Oncologic Interventions for the Rising Burden of Young Adult Cancer	88
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	88
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy	87
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	86
Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth	86
A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells	85
Akk Abundance Alters Survival in Patients with NSCLC on ICIs	85
Noninvasive and Multicancer Biomarkers: The Promise of LINE-1 Retrotransposons	84

Bridging the Gap between Diseases of the Stomach and Lower Esophagus	84
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology	83
Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL	83
Atypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53	80
New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma	80
Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer	80